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Abstract: Allergic rhinitis is the most common atopic disorder seen in the outpatient clinic 
setting diagnosed by history, physical exam and objective testing. According to the Allergic 
Rhinitis and its Impact on Asthma (ARIA) document, it is classiﬁ  ed by chronicity (intermittent 
or persistent), and severity which is based on symptoms and quality of life (mild, or moder-
ate/severe). It has enormous socioeconomic costs and signiﬁ  cant reduction in quality of life. 
Allergen avoidance should be implemented, particularly in children, to reduce level of exposure; 
unfortunately efforts are often inadequate. Montelukast, a novel medication, is an antagonist 
to the leukotriene receptor. It is nonsedating, dosed once daily, and has a safety proﬁ  le similar 
in adults and children with approval down to 6 months of age. A review of the literature un-
doubtedly establishes montelukast as a viable alternative for the treatment of seasonal allergic 
rhinitis. Its beneﬁ  ts are equivalent to antihistamines, when used as monotherapy, but less than 
intranasal corticosteroids. The addition of an antihistamine to montelukast does appear to have 
added beneﬁ  ts and at times is reported to be equivalent to intranasal corticosteroids. 
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Introduction
Allergic rhinitis (AR) is the most common atopic disorder affecting some 20 to 40 
million people annually in the US, including 10% to 30% of adults and up to 40% of 
children (Dykewicz et al 1998). Many believe this to be a conservative estimate with 
about one third of persons burdened with allergic rhinitis not seeking formal medical 
care (McMenamin 1994). The prevalence of AR has continued to increase during the 
past decades from 10% in 1970 to 30% in 2000 with severity ranging from mild to 
debilitating (Dykewicz et al 1998; Nathan et al 1997). The morbidity associated with 
AR is profound; attributing to 3.4 million lost workdays yearly, diminished work pro-
ductivity, and cognition (McMenamin 1994). This morbidity is not only attributable 
to symptoms but also soporiﬁ  c effects of sedating antihistamines purchased over-the-
counter by many patients. Direct and indirect costs associated with treating AR are 
substantial and reported to be US$5.3 billion in the year 1996 (Ray et al 1999). 
The pathophysiology of AR is characterized by inﬂ  ammation of the nasal mu-
cous membranes because of a complex response to nasal allergen exposure. Nasal 
congestion, sneezing, nonpurulent rhinorrhea as well as pruritis of the eyes, palate, 
and nose characterize the symptoms experienced by patients. If severe, problems may 
include paranasal sinus pressure and pain or eustachian tube dysfunction described as 
ear popping and fullness (Dykewicz et al 1998). According to the Allergic Rhinitis 
and its Impact on Asthma (ARIA) document, AR should be classiﬁ  ed by chronicity 
(intermittent or persistent), and severity which is based on symptoms and quality of 
life (mild, or moderate/severe) (Bousquet et al 2001) (Table 1). The terms “seasonal” 
and “perennial” AR were previously categorized as AR by the clinically signiﬁ  cant Therapeutics and Clinical Risk Management 2007:3(2) 328
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aeroallergen. Perennial AR is associated with year round 
and indoor allergens including mold spores, cockroaches, 
dust mite fecal particles, animal dander, and occupational 
exposure. Seasonal AR is commonly referred to as “hay 
fever”, developing during a deﬁ  ned pollen season, and is 
usually intermittent, as a result of allergic reactions to outdoor 
aeroallergens including mold spores, and pollens of trees, 
grasses, and weeds that depend on wind for cross-pollination. 
Commonly there is an overlap of “perennial” and “seasonal” 
symptoms in some geographic regions which has resulted in 
decreased use and confusion regarding these terms.
In a sensitized person, allergens exposed to the nasal 
mucosa initiate the allergic response by degranulation of 
preformed and newly synthesized mediators from mast cells 
after the cross linkage of cell-bound immunoglobulin E 
(IgE). An early-phase response develops because of cysteinyl 
leukotrienes (CysLTs), prostaglandins, histamine, tryptase, 
neuropeptides, and cytokines resulting in sneezing, pruritis, 
rhinorrhea, and congestion. During the late-phase, congestion 
primarily develops in response to cytokines, mediator release, 
and the inﬁ  ltration of inﬂ  ammatory cells including basophils, 
eosinophils, neutrophils, mast cells, and mononuclear cells 
4–6 hours after allergen exposure (White and Kaliner 1992; 
Togias 2000). These cells in turn also release mediators in-
cluding CysLTs, histamine, kinins, and eosinophil-derived 
mediators which are responsible for recruitment, activation, 
and perpetuation of cellular inﬁ  ltrate resulting in continued 
chronic nasal congestion during the late phase (Ledford and 
Lockey 1998). 
On physical examination, patients classically can have 
pale nasal mucosae with swollen, edematous turbinates, and 
clear nasal secretions (rhinorrhea). A thorough history and 
physical are sufﬁ  cient to make a preliminary diagnosis and 
initiate treatment.  Demonstrating speciﬁ  c IgE antibodies by 
either skin testing or in vitro radioallergosorbent (RAST) 
testing to which a person has become sensitized may be 
necessary in patients with difﬁ  cult to treat allergic rhinitis 
in order to provide optimal treatment. Current treatment 
approaches include nonpharmacologic measures to reduce 
exposure to offending allergens and pharmacotherapy that in-
cludes several different classes of drugs. Optimal therapeutic 
drug selection depends upon several factors including sever-
ity (mild, moderate, or severe) and duration (intermittent, 
persistent) of symptoms, patient adherence (which includes 
dosing frequency, willingness to accept the mechanism of 
delivery and cost) and the clinician assessment of which 
pharmacologic class best treats a speciﬁ  c patient since not 
all agents are equally effective in all patients.
Nasal provocation testing although more commonly used 
in research than in the clinical setting, is useful in diagnosing 
and conﬁ  rming sensitivity in occupational rhinitis, evaluating 
discrepancies between history and test(s), and to test for non-
speciﬁ  c reactivity to stimuli commonly observed in allergic 
rhinitis (Corrado et al 1986; Gerth-van-Wijk and Dieges 
1991; Malm et al 1999). One method of provocation is with 
adenosine monophosphate (AMP), which acts indirectly via 
primed airway mast cells causing degranulation and release 
of mediators and in this manner acts a surrogate for airway 
inﬂ  ammation.
Treatment
Optimal treatment of allergic rhinitis depends upon several 
factors. The ﬁ  rst involves avoidance of implicated aller-
gens. This remains the cornerstone of treatment in allergic 
disease; however two Cochrane meta-analysis (Gotzsche 
et al 1998; Kilburn et al 2001) and an ARIA position paper 
have brought this into question (Custovic and van Wijk 
2005). In adults, the general consensus is that physical and 
chemical methods used to control dust mite and pet allergen 
levels is not supported when used as single or even multiple 
interventions. Whereas in children, environmental control 
measures do offer beneﬁ  t and should be implemented when 
appropriate (Bjornsdottir et al 2003; Custovic and van Wijk 
Table 1 Revised classiﬁ  cation of AR from ARIA guidelines. 
Copyright © 1992. Reproduced with permission from Corren J, 
Adinoff AD, Irvin CG. 1992. Nasal beclomethasone prevents the 
seasonal increase in bronchial responsiveness in patients with
allergic rhinitis and asthma. J Allergy Clin Immunol, 90:250–6.
Classiﬁ  cation of allergic rhinitis
1- “Intermittent” means that the symptoms are present:
     • Less than 4 days a week,
     • Or for less than 4 weeks.
2- “Persistent” means that the symptoms are present:
     • More than 4 days a week,
     • And for more than 4 weeks.
3- “Mild” means that none of the following items are present:
     • Sleep disturbance,
     • Impairment of daily activities, leisure and/or sport,
     • Impairment of school or work,
     • Troublesome symptoms.
4- “Moderate-severe” means that one or more of the following items are 
present:
     • Sleep disturbance,
     • Impairment of daily activities, leisure and/or sport,
     • Impairment of school or work,
     • Troublesome symptoms. 
Abbreviations: AR, allergic rhinitis; ARIA, Allergic Rhinitis and its Impact on 
Asthma.Therapeutics and Clinical Risk Management 2007:3(2) 329
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2005). Unfortunately, the effort to appropriately reduce 
levels of indoor allergens is often too difﬁ  cult for patients 
to accomplish and even more difﬁ  cult is the prevention of 
exposure to outdoor allergens. 
Pharmacotherapy includes oral and intranasal H1 
antihistamines, intranasal corticosteroids, oral and intranasal 
decongestants, intranasal anticholinergics, intranasal 
cromolyn and leukotriene receptor antagonists. Tradition-
ally, the selection of medication has been dependant on 
severity, intermittent versus persistent AR, and physician 
preference. A recent study found therapy chosen by physi-
cians in an ad hoc fashion to be less effective than therapy 
directed by speciﬁ  c guidelines (Bousquet et al 2003). Several 
guidelines have recently been published and include: Allergy 
Report, Joint Task Force on Practice Parameters for Rhinitis, 
European Academy of Allergology and Clinical Immunol-
ogy, and ARIA (Dykewicz et al 1998; AAAAI 2000; van 
Cauwenberge et al 2000; Bousquet et al 2001). None of the 
guidelines recommend oral ﬁ  rst-generation antihistamines 
as part of treatment for AR. Second generation H1 antihis-
tamines are in general recommended for mild to moderate 
disease as ﬁ  rst line therapy, but not when treating nasal 
congestion. Oral decongestants are indicated in combination 
with oral antihistamines for nasal congestion, but patients 
should be monitored for side effects including elevated 
blood pressure, palpitations, tremor, sleep disturbance and 
should be used with caution in patients with certain condi-
tions, eg, arrhythmia, coronary heart disease, hypertension, 
hyperthyroidism, glaucoma, diabetes, and urinary dys-
function (Jordana et al 1996). Topically applied intranasal 
decongestants should be limited in use to less than 10 days 
because prolonged use may lead to tachyphylaxis (rhinitis 
medicamentosa), which is a rebound swelling of the nasal 
membranes or drug induced rhinitis (Graf et al 1995; Graf 
and Hallen 1996). Intranasal corticosteroids (long consid-
ered the “gold standard”) are often required in moderate to 
severe disease and are effective in reducing all symptoms 
of allergic rhinitis in addition to eye symptoms associated 
with allergic conjunctivitis (Bernstein et al 2004; Singulair 
PI 2005). Mast cell stabilizers are regarded as safe, but are 
usually less effective than antihistamines and nasal cortico-
steroids expect, perhaps, in a prophylactic role. Intranasal 
anticholinergic sprays are recommended to reduce rhinorrhea 
and/or postnasal drainage not controlled by other medica-
tions. However, as a class, anticholinergics have few effects 
on other symptoms of AR. The other major therapeutic class 
of drug indicated for AR therapy is the leukotriene-receptor 
antagonist (LTRA) to which montelukast belongs. There 
were no comments in 4 of 5 guideline statements at time of 
the publications, which has led many in the health ﬁ  eld to 
question its place in treatment. The guidelines did mention 
that antileukotriene medications, such as montelukast, may 
be of value in the treatment of AR and further testing was 
needed to fully evaluate efﬁ  cacy. Research since the various 
guideline publications continues and there are now sufﬁ  cient 
data to make the use of LTRA for the treatment of AR a 
reasonable option. This article is intended to inform physi-
cians and other healthcare professionals about montelukast’s 
pharmacology, efﬁ  cacy, tolerability, and therapeutic role in 
the management of AR. 
Pharmacology
Montelukast is an orally active, highly selective cysteinyl 
leukotriene type-1 receptor antagonist of leukotreine D4, 
with affinities approximately two-fold greater than the 
natural ligand. It is rapidly absorbed achieving peak plasma 
concentration (Cmax) in 3 to 4 hours and with a mean bio-
availability of 64% following a 10 mg oral administration. 
For the 5 mg chewable, Cmax is achieved in 2 to 2.5 hours 
with mean bioavailability of 73% fasting versus 63% with 
a standard meal. Regarding the 4 mg chewable, the mean 
Cmax is achieved in 2 hours, with fasting, for patients in 2 to 
5 year old range. More than 99% is bound to plasma proteins 
with minimal distribution across the blood–brain barrier. 
Metabolism occurs via liver P450 (CYP) 3A4 and 2CP 
microsomes, with potent inhibition of P450 2C8. Excretion 
occurs almost exclusively in bile with a half-life from 2.7 to 
5.5 hours in healthy adults. The pharmacokinetic proﬁ  le is 
similar in females and males, young and elderly. 10 mg is 
recommended for ages 15 and older, 5 mg chewable tablets 
for patients 6 to 14 years of age, 4 mg chewable in patients 
2 to 5 years of age, and 4 mg oral granule formulation in 
pediatrics for asthma in 12 to 23 months and AR in 6 to 23 
months of age. In patients with mild to moderate hepatic 
insufﬁ  ciency, no dosage adjustment is required but data are 
lacking regarding severe hepatic impairment. Because mon-
telukast and its metabolites are almost exclusively excreted in 
bile and not urine, it has not been evaluated in patients with 
renal insufﬁ  ciency. Drug interactions were noted to not to be 
clinically signiﬁ  cant with theophylline, and did not change 
the pharmacokinetics proﬁ  le of warfarin about prothrombin 
time or international normalized ratio (INR). Urinary excre-
tion of digoxin is not altered and there is no change in the 
plasma concentration proﬁ  le with terfenadine. Prolongation 
of QTc was not observed with coadministration of terfenadine 
(Markham and Faulds 1998; Singulair PI 2005). Therapeutics and Clinical Risk Management 2007:3(2) 330
Lagos and Marshall
Tolerability
Montelukast is well tolerated and has a safety proﬁ  le simi-
lar in pediatric and adult populations. In studies looking at 
safety and adverse effects, in general, there was no clinical or 
laboratory difference in adverse experiences versus placebo. 
Side effects most commonly reported above placebo included 
headache, otitis media, upper respiratory infection, and phar-
yngitis. These events occurred at a frequency of 2% above 
placebo (Markham and Faulds 1998; Singulair PI 2005). Night 
terrors, although not commonly reported, can develop.
Efﬁ  cacy and qualify of life
The efﬁ  cacy of montelukast in the treatment of seasonal 
AR has been studied quite extensively over the past few 
years as monotherapy, combined with a second generation 
antihistamine, and with or without intranasal corticosteroids. 
Several studies evaluating the efﬁ  cacy of montelukast as 
monotherapy were large, double blind, placebo-controlled 
trials (Meltzer et al 2000; Nayak et al 2002; Philip et al 
2002, 2004; van Adelsberg, Philip, LaForce, et al 2003; van 
Adelsberg, Philip, Pedinoff, et al 2003). Statistically signiﬁ  -
cant endpoints in symptom scores compared with placebo 
included daytime nasal symptoms scores (in 5 of 6 studies), 
daytime eye symptom scores, nighttime symptom scores, and 
composite symptom scores. Nighttime symptoms (difﬁ  culty 
falling asleep, nighttime awakenings, and congestion upon 
awaking) appeared to have a better response with montelu-
kast compared with antihistamines as reported in 3 separate 
studies (Philip et al 2002; Nayak et al 2002; van Adelsberg, 
Philip, LaForce, et al 2003). 
In studies evaluating montelukast combined with ceteri-
zine or loratadine versus monotherapy, the data are largely 
equivocal. In a study performed by Meltzer and colleagues 
(2000) the combination of montelukast and loratadine taken 
concomitantly provided a signiﬁ  cant improvement in daily 
diary cards, Rhinoconjunctivitis Quality of Life Question-
naire (RQLQ), compared with placebo and each agent alone. 
In a second study (Kurowski et al 2004), the combination 
of montelukast with ceterizine did show additive beneﬁ  ts in 
achieving decreased scores when compared with both mono-
therapies while another study (Nayak et al 2002) showed 
no statistically signiﬁ  cant symptom improvement with the 
combination treatment compared with either montelukast or 
loratadine alone. Even though no statistical signiﬁ  cance was 
observed, there was a trend toward increased improvement 
of symptoms compared with monotherapy. 
The data comparing intranasal corticosteroids with mono-
therapy of montelukast or antihistamine show nasal steroids 
to have a greater efﬁ  cacy on daytime and nighttime symptoms 
(Pullerits et al 2002; Ratner et al 2003; Martin et al 2005). 
However, when intranasal corticosteroids are compared with 
combination therapy with montelukast and antihistamines, 
results vary depending on the antihistamine chosen (ie, 
cetirizine vs loratadine) and which intranasal corticosteroid 
was used (ie, ﬂ  uticasone vs budesonide vs mometasone). 
In one study comparing ﬂ  uticasone with a combination of 
montelukast and loratadine, both groups showed improve-
ments in daytime nasal allergic symptoms compared with 
placebo, but ﬂ  uticasone was superior in controlling nighttime 
symptoms (Pullerits et al 2002). Conversely, the combination 
of montelukast and cetirizine was as effective as intranasal 
mometasone in patients with allergic rhinitis, and intranasal 
budesonide in patients with seasonal AR and asthma (Wilson, 
Orr, et al 2001; Wilson, Sims, et al 2001). Lastly, further 
beneﬁ  t is shown in patients already treated with intranasal 
corticosteroids and antihistamines when montelukast is added 
for uncontrolled symptoms of AR.
In addition to symptom scores, studies with RQLQ 
resulted in modest but signiﬁ  cant improvements for both 
antihistamines and montelukast as monotherapy compared 
with placebo (Topuz and Ogmen 2003; Perry et al 2004; Patel 
et al 2005). Not all parameters responded equally with non-
nose and non-eye symptoms being cited as not improving 
with montelukast (Perry et al 2004). Combination therapy 
resulted in greater beneﬁ  ts in reducing scores within all 
RQLQ domains as compared with single agent treatment 
(Perry et al 2004; Patel et al 2005). 
The efﬁ  cacy of montelukast in the treatment of perennial 
AR has not been studied as extensively as in seasonal AR. 
There was one large placebo controlled trial, with reported 
improvements in daytime nasal score symptoms, quality of 
life, as well as improvements in Global Evaluation of Allergic 
Rhinitis by patients (Patel et al 2005). A second study evaluat-
ing cat allergen exposure on lower and upper airways showed 
a trend in improvement in the primary endpoint of nasal 
symptoms score and signiﬁ  cant beneﬁ  t with nasal congestion 
during both allergen challenge and the recovery phase (Perry 
et al 2004). Additionally, analysis of simultaneous lower and 
upper airway responses showed more patients were protected 
from both asthma and rhinitis with montelukast compared 
with placebo (Phipatanakul et al 2002).
Conclusions
Montelukast belongs to a unique class of drugs that speciﬁ  -
cally target the cysteinyl leukotriene receptor 1. A review of 
the literature supports the claim of montelukast as a viable Therapeutics and Clinical Risk Management 2007:3(2) 331
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alternative for the treatment of seasonal AR. Its beneﬁ  ts are 
generally equivalent to antihistamines when used as mono-
therapy regarding efﬁ  cacy and quality of life improvement, 
but less than intranasal corticosteroids. The addition of an 
antihistamine to montelukast does appear to have added ben-
eﬁ  ts and may be equivalent to intranasal corticosteroids, at 
least in some patients. More research needs to be completed 
in order to determine montelukast’s true efﬁ  cacy in treating 
perennial AR, but early studies appear favorable. 
Treatment with montelukast is slightly more complicated 
than asking the question “where does montelukast belong 
in therapy” as there are many factors a physician needs 
to consider in selecting a medication. Severity, perennial 
versus seasonal and associated comorbidities all should 
be considered. Cost is another factor often overlooked by 
those prescribing medications. In treating mild AR, either 
montelukast or a second generation antihistamine may be 
chosen because of comparable efﬁ  cacy. If no improvement is 
appreciated, changing to ICS may generally be more effective 
than adding of a second medication. The use of an inhaled 
corticosteroid (ICS) as ﬁ  rst line treatment is also acceptable 
in mild disease. When disease progresses to a moderate or 
severe classiﬁ  cation, most professionals agree that ICS re-
mains the ﬁ  rst line agent in treatment of AR. In those patients 
with less than optimal improvement on ICS alone, careful 
questioning about regular use of the product is extremely 
important. Add on therapy with a 2nd generation antihista-
mine may often be a better choice particularly in those who 
will not or cannot use the ICS regularly as prescribed. The 
selection of the antihistamine is not based on relevant data 
but from a ﬁ  nancial perspective because second generation 
antihistamines are now available over the counter and in 
generic form and therefore more cost effective. However, 
the 2nd and even 3rd generation antihistamines are not com-
pletely devoid of sedating effects (except fexofenadine) and 
should therefore be carefully considered if prescribed for a 
patient. In those who continue with symptoms despite double 
therapy, Topuz and colleagues (2003) showed about 10% of 
patients will beneﬁ  t with the addition of montelukast. Lastly, 
the selection of montelukast will also depend on comorbid 
conditions. This is exempliﬁ  ed by the coexistence of AR in 
up to 78% of patients with asthma having coexisting AR, 
which contrasts with the prevalence in the general popula-
tion of 20%. Likewise 3%–5% of asthmatics in the general 
population have AR compared with 19%–38% of patients 
with allergic rhinitis having coexisting asthma. The united 
airway has been proposed to explain these associations sup-
ported in part by the continuous respiratory mucosa, include 
the occurrence of bronchial hyperreactivity following nasal 
provocation test in ARs without asthma, and improvement 
in asthma control after treatment of AR with intranasal cor-
ticosteroids (Welsh et al 1987; Corren et al 1992; Corren 
1997). Likewise, selecting montelukast in this group of 
patients is beneﬁ  cial because of its proven efﬁ  cacy in both 
conditions. Again this needs to be adjusted on an individual 
patient basis because of the severity of asthma and AR. 
Patients may require intranasal corticosteroids in addition to 
antileukotrienes and antihistamines. Further studies need to 
be performed in order to fully delineate the optimal treatment 
strategies regarding pharmacotherapy. The guidelines do not 
infer preference of medications at this time, but only instruct 
us in the stepping up and down of treatment.
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